Janssen debuts schizophrenia awareness doc

Share this article:
Janssen debuts schizophrenia awareness doc
Janssen debuts schizophrenia awareness doc
Johnson & Johnson is back in the film game with Janssen's half-hour documentary Living with Schizophrenia: A Call for Hope and Recovery.

The unbranded film, which follows several young people with schizophrenia and their families, aims to lessen the fear and stigma associated with the condition. It debuted Friday in Washington, DC, and will be distributed through a series of community-based events, via advocacy groups and online at hopeandrecoveryfilm.com.

The film, said director Emily Abt, “highlights the stories that don't make the headlines – the stories of hope and promise.” Abt's grandmother struggled with schizophrenia.

Janssen's Risperdal and Invega franchises are indicated for the treatment of schizophrenia, and the company sponsored an earlier documentary on the topic. In 2007, J&J's Centocor unit sponsored “Innerstate” an hour-long documentary following a similar formula, following several young people struggling with autoimmune disorders. Centocor makes Remicade for rheumatoid arthritis, psoriasis and Crohn's Disease.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, ...

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.